From Slides To Sensemaking: The Future Of The Presentation

Leaders don’t need more slides—they need more sensemaking. The future of presentations is clarity, story, and presence, not ...
The Manila Times

Xilio Therapeutics to Present Phase 2 Data for Vilastobart Highlighting Response Rate in Patients with MSS mCRC and High Plasma Tumor Mutational Burden as a Late-Breaking ...

Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that ...

Incyte Corporation (INCY) Discusses ESMO Data on TGF-beta Receptor by PD-1 Bispecific in Colorectal Cancer and G12D Inhibitor in Pancreatic Cancer Transcript

Discusses ESMO Data on TGF-beta Receptor by PD-1 Bispecific in Colorectal Cancer and G12D Inhibitor in Pancreatic ...
Targeted Oncology

Efficacy, Safety of 212Pb-DOTAMTATE in PRRT-Naive Patients With GEP-NETs

A groundbreaking study reveals promising efficacy and safety of 212Pb-DOTAMTATE for treating neuroendocrine tumors, paving the way for future trials.
Cantech Letter

Walker Lane Resources Ltd. Announces An Aeromagnetic and Radiometric Airborne Survey will be Completed on its Tule Canyon Project, Walker Lane …

YL VANCOUVER, BC, Oct. 27, 2025 /CNW/ – Walker Lane Resources Ltd. (TSXV: WLR) (Frankfurt: 6YL); “Walker Lane”) is pleased to ...

Nautilus (NAUT) Q3 2025 Earnings Call Transcript

Research and Development Expenses -- $9.6 million in the third quarter of 2025, down from $12.3 million in Q3 2024, due to ...